NCT03606967 2026-04-02
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
92 trialsNCT02886065 2026-03-13
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT02287428 2026-03-12
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05098210 2026-03-12
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT03358719 2026-02-27
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT07430202 2026-02-24
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Not yet recruiting
NCT07300475 2026-02-13
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT06529822 2026-01-13
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Washington University School of Medicine
Phase 1 Recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT05010200 2026-01-07
PGV-Prostate
Icahn School of Medicine at Mount Sinai
Phase 1 Active not recruiting
NCT01970358 2025-12-29
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT06411691 2025-12-18
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT06564623 2025-12-05
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT04117087 2025-12-03
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04248569 2025-12-03
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT05013216 2025-12-03
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT06782932 2025-12-03
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Recruiting
NCT05111353 2025-11-05
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Washington University School of Medicine
Phase 1 Completed
NCT05283109 2025-10-31
ETAPA I
Duke University
Phase 1 Active not recruiting
NCT02826434 2025-10-01
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT03223103 2025-09-10
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Albert Einstein College of Medicine
Phase 1 Active not recruiting
NCT04201873 2025-08-22
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04116320 2025-07-14
AM-003
University of Virginia
Phase 1 Terminated
NCT05025488 2025-04-06
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Icahn School of Medicine at Mount Sinai
Phase 1 Recruiting
NCT03206047 2025-03-13
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT06614140 2024-09-26
Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors
Seqker Biosciences, Inc.
Phase 1/2 Active not recruiting
NCT06064279 2024-09-19
HAITEN-ICI
VA Office of Research and Development
Phase 1/2 Withdrawn
NCT03956056 2024-07-17
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Washington University School of Medicine
Phase 1 Terminated
NCT02924038 2024-06-14
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
University of California, San Francisco
Phase 1 Terminated
NCT02834052 2024-06-07
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
Augusta University
Phase 1/2 Completed
NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed
NCT06343077 2024-04-02
Intratumoral and Systemic HiltonolĀ® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT03789097 2024-01-30
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT03121677 2023-08-14
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Washington University School of Medicine
Phase 1 Terminated
NCT01188096 2023-06-12
Poly-ICLC
Wake Forest University Health Sciences
Phase 2 Completed
NCT03359239 2023-05-16
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT04799431 2023-05-09
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Withdrawn
NCT02166905 2023-02-24
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT00616941 2022-10-12
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT01810016 2022-10-12
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT05557240 2022-10-12
Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
Shanghai 10th People's Hospital
Phase NA Unknown
NCT02334735 2022-09-15
A Comparison of Matured Dendritic Cells and MontanideĀ® in Study Subjects With High Risk of Melanoma Recurrence
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT03262103 2022-09-10
Neoadjuvant HiltonolĀ® (PolyICLC) for Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT01834248 2022-07-22
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT05281926 2022-03-16
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
National Taiwan University Hospital
Phase 1 Unknown
NCT02427581 2022-03-10
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Washington University School of Medicine
Phase 1 Withdrawn
NCT02873819 2022-03-08
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Gliknik Inc.
Phase 2 Completed